Editas Medicine, Inc. (EDIT) vs ARS Pharmaceuticals, Inc. (SPRY)
A side-by-side comparison of Editas Medicine, Inc. and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EDIT
Editas Medicine, Inc.
$2.74HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
SPRY
ARS Pharmaceuticals, Inc.
$4.28HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT
Total return — EDIT vs SPRY
growth of $100 · dividends reinvested · last 6yEDIT -91.6% (-33.8%/yr)SPRY -82.8% (-25.5%/yr)SPRY compounded faster over this window
EDIT SPRY
EDIT vs SPRY: by the numbers
- •SPRY is the larger company ($425M vs $420M market cap).
- •Both run net losses; EDIT's is the smaller (-157.32% vs -184.24% net margin).
- •SPRY grew revenue faster over the past five years (36.43% vs -10.34% CAGR).
Metrics side by side
Valuation
| Metric | EDIT | SPRY |
|---|---|---|
| P/S ratio | 8.95 | 3.63 |
| P/B ratio | 3.99 | 33.97 |
Profitability
| Metric | EDIT | SPRY |
|---|---|---|
| Gross margin | 100.00% | 73.89% |
| Operating margin | -245.15% | -212.92% |
| Net margin | -157.32% | -184.24% |
| ROE | -70.24% | -1721.80% |
| ROIC | -48.61% | -114.65% |
Growth (annualized)
| Metric | EDIT | SPRY |
|---|---|---|
| Revenue CAGR (5Y) | -10.34% | 36.43% |
| Total return CAGR (5Y) | -40.76% | -16.35% |
Frequently asked
- Which has grown faster, EDIT or SPRY?
- Over the past five years, SPRY grew revenue faster — EDIT at a -10.34% CAGR versus SPRY at 36.43%.
- How have EDIT and SPRY total returns compared?
- Over the past 5 years, EDIT delivered -40.76% and SPRY delivered -16.35% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Editas Medicine ROEARS Pharmaceuticals ROEEditas Medicine operating marginARS Pharmaceuticals operating marginEditas Medicine revenue growthARS Pharmaceuticals revenue growthEditas Medicine free cash flowARS Pharmaceuticals free cash flow
Editas Medicine & ARS Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.